SQZ vs. TCBP, ACORQ, SCNI, ACOR, GMDAQ, GMDA, ELOX, ALBT, KRBP, and FNCH
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include TC Biopharm (TCBP), Acorda Therapeutics (ACORQ), Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACOR), Gamida Cell (GMDAQ), Gamida Cell (GMDA), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Kiromic BioPharma (KRBP), and Finch Therapeutics Group (FNCH). These companies are all part of the "biological products, except diagnostic" industry.
TC Biopharm (NASDAQ:TCBP) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
TC Biopharm has a net margin of 0.00% compared to TC Biopharm's net margin of -369.96%. SQZ Biotechnologies' return on equity of 0.00% beat TC Biopharm's return on equity.
TC Biopharm has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500.
16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 0.1% of TC Biopharm shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
SQZ Biotechnologies received 9 more outperform votes than TC Biopharm when rated by MarketBeat users. Likewise, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 50.00% of users gave TC Biopharm an outperform vote.
TC Biopharm has higher earnings, but lower revenue than SQZ Biotechnologies.
In the previous week, TC Biopharm had 5 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 6 mentions for TC Biopharm and 1 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.28 beat TC Biopharm's score of 0.00 indicating that TC Biopharm is being referred to more favorably in the media.
Summary
TC Biopharm beats SQZ Biotechnologies on 7 of the 13 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
